Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A first-in-human study evaluating safety, PK, and PD of a novel universal anticoagulant reversal agent, OKL-1111.

Blood vessels, thrombosis & hemostasis·2026
Same author

Red blood cell-derived transglutaminase 2 influences thrombus formation.

Research and practice in thrombosis and haemostasis·2026
Same author

<i>F9</i> missense variant hot spots associated with qualitative protein defects causing hemophilia B.

Blood vessels, thrombosis & hemostasis·2025
Same author

Transforming sepsis management: AI-driven innovations in early detection and tailored therapies.

Critical care (London, England)·2025
Same author

Structure and interactions of the proteins from the contact system.

Blood·2025
Same author

Rediscovering nitroxoline: a metal-chelating agent bridging infection and cancer.

Drug discovery today·2025

Related Experiment Video

Updated: May 30, 2026

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
06:06

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Protein C inhibitor.

Joost C M Meijers1, Heiko Herwald

  • 1Departments of Vascular Medicine and Experimental Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. j.c.meijers@amc.uva.nl

Seminars in Thrombosis and Hemostasis
|August 2, 2011
PubMed
Summary

Protein C inhibitor (PCI) is a versatile serine protease inhibitor. This review explores its roles in hemostasis, fertilization, and intracellular functions, despite its broad enzyme specificity and unknown biological function.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Experiment Videos

Last Updated: May 30, 2026

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles
06:06

Protein Kinase C-delta Inhibitor Peptide Formulation using Gold Nanoparticles

Published on: March 9, 2019

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Physiology

Background:

  • Protein C inhibitor (PCI) is a serine protease inhibitor.
  • Initially identified as an inhibitor of activated protein C (APC).
  • PCI exhibits broad enzyme specificity, inhibiting proteases in coagulation, fibrinolysis, cancer, wound healing, and fertility.

Purpose of the Study:

  • To review the specific roles of PCI in hemostasis, thrombosis, and fertilization.
  • To present the latest information on PCI's intracellular processes, phospholipid binding, and bacterial killing capabilities.

Main Methods:

  • Literature review of existing research on Protein C inhibitor.
  • Analysis of studies investigating PCI's enzymatic activity and biological functions.
  • Synthesis of current knowledge regarding PCI's involvement in various physiological and pathological processes.

Main Results:

  • PCI plays significant roles in hemostasis and thrombosis.
  • PCI is implicated in fertilization processes.
  • Emerging evidence suggests PCI participates in intracellular functions, phospholipid binding, and bacterial killing.

Conclusions:

  • The broad specificity and diverse functions of PCI contribute to its complex biological role.
  • Further research is needed to fully elucidate the biological function of PCI, particularly given the lack of suitable animal models.
  • Understanding PCI's multifaceted roles is crucial for potential therapeutic applications in thrombosis, fertilization, and infectious diseases.